Saturday, February 4, 2023

They investigate a third death in trials of an experimental drug against Alzheimer’s


  • Lecanimab was presented as a great hope, but doubts about the usefulness of the results have been added to the investigation of three deaths that were not reported by drug companies.


  • The third deceased is a 79-year-old Florida woman who had no other disease other than Alzheimer’s.


  • Woman develops headache a few days after second dose of lecanumab

is the last a 79-year-old Florida woman whose medical records have been accessed by the Journal science, He died in mid-September after suffering large brain hemorrhage, As happened in the last two cases. Scientific Magazine has consulted several experts who believe the death is likely directly linked to lecanumab.

Furthermore, neither Eisai nor Biogen have reported on this latest death, despite the fact that it occurred in mid-September and held a conference in November to detail the results of the Phase 3 clinical trials. it was done. Eisai, which is responsible for the trial, assures that yes the FDA (US agency responsible for drug authorization) has been informed.

Investigating the cause of death is not easy. The study was carried out with 1,800 people with Alzheimer’s and because of their age it is likely that some will die during the investigation. Eisai has reported 13 deaths and assured they were not related to lecanmab, but has not made public the history of each dead person and no one has been able to independently verify it. are added to Three deaths known to magazine investigation state why scienceNot for the transparency of the company.

Lecanumab, like other experimental Alzheimer’s drugs, targets the amyloid beta protein, which for years has been thought to be the most likely cause of the disease, according to a recently challenged theory. According to this hypothesis, the accumulation of these proteins in plaques leads to the death of brain cells and, consequently, loss of memory and abilities. The problem is that these drugs, By destroying amyloid beta plaques, they can also cause bleeding. This is included in the potential side effects of drugs such as lecanumab, but is considered mild, not fatal.

Lecanumab is suspected to cause a weakening of the blood vessels which may increase the chances of a more serious event. The previous two deaths were related to patients taking blood thinners. The Florida woman also received a small dose of heparin, although in this case, several neurologists consulted. science They don’t believe it was conclusive.

The family of this patient has assured that after receiving the second dose of lecanumab, The woman complained of a headache and could not complete the sentences, feeling confused. It was on September 14 when he faced a serious health crisis and had to be admitted.

Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news